Advertisement

Picture Kentro Design Is Key to Your Success Berlin 650x100px
Financing › Details

Insempra–SEVERAL: investment, 202405 financing round Series A $20m with existing + new investors

 

Period Period 2024-05-07
  Predecessor Origin.bio–SEVERAL: investment, 202105 financing round $15m led by EQT Ventures
Organisations Money taker Insempra GmbH
  Money source SEVERAL
Products Product biomaterials
  Product 2 venture capital
Person Person Persson, Ted (EQT 202405 Partner at EQT Ventures)
     

Insempra GmbH. (5/7/24). "Press Release: Insempra Completes $20 Million Financing to Advance the Development of Next-generation Bio-based Ingredients". Munich.

Series A investment round will accelerate Insempra’s market-first approach to developing superior, intrinsically sustainable ingredients for the beauty & food industries.


Insempra, today announces the successful completion of a $20 million Series A financing round.

Following an initial $15m seed round conducted in 2021 [ as Origin.bio; iito ], this financing round will enable Insempra, to continue building a technology platform that delivers high-performance, intrinsically sustainable ingredients for a wide range of industries, while supporting the company in the scale up of its technology scouting, development, and manufacturing capabilities.

Existing investors EQT Ventures, BlueYard Capital, Possible Ventures, Taavet Sten and Acequia Capital participated in the round. New investors are the corporate venture of international FMCG giant Henkel, Henkel dx Ventures, Bayern Kapital and Alante Capital.

Inspired to create a better future in collaboration with nature, Insempra takes a market-first approach to developing its science, creating ingredients that customers need. By harnessing new technologies to advance biological manufacturing processes, the company creates naturally superior products to drive the regenerative revolution. Insempra designs and builds these ingredients with atomic precision so that they can be rapidly produced and manufactured at scale, offering better solutions to agriculturally and petrochemically sourced oils and materials.

Driven by market need and collaborations with world-wide renowned consumer brands, Insempra is growing lipids for cosmetic and food applications. It is also developing technology that offers a bio-based alternative to everyday materials such as polymers and textiles and progressing its biological solutions to create new natural molecules for use in functional ingredients, such as antioxidants and preservatives and flavours and fragrances.

Jens Klein, founder, and CEO of Insempra, commented: “We are grateful for the support of this group of investors who have recognized the potential of Insempra’s market-first approach and innovative technology platforms. Working in collaboration with nature, we will continue to expand our capacity to develop intrinsically sustainable materials that are superior in quality and will reduce our dependency on chemical industrialization processes.”

Ted Persson, Partner at EQT Ventures, added: “Insempra has both the team and the technology to drive a revolution in industrial manufacturing and gain rapid market traction for its products. New technology platforms such as Insempra’s have the potential to dramatically change the manufacturing processes of multiple multibillion-dollar industries, developing customized ingredients to fit market needs.”


About Insempra

Insempra is a biotechnology-powered company enabling businesses to transform their ingredient lists with superior products made in collaboration with nature. For too long, businesses have relied on petrochemical production and environmental exploitation, depleting our limited natural resources, and polluting our planet.

Environmental issues, consumer demand, and regulatory restrictions are changing the ingredient landscape dramatically. The beauty & personal care, food & nutrition, and fashion industries are under immense pressure to shift to sustainable alternatives. Insempra’s advanced technology platform enables the production of superior natural ingredients on an industrial scale to help the world’s leading brands transform their products.

Together, it is our mission to grow a better future.

Learn more about Insempra at insempra.bio


Enquiries

Insempra GmbH
Nicole Laurence
Marketing & Communications
nicole.laurence@insempra.bio
Insempra GmbH
82152 Munich
Germany


Participating Investors

EQT Ventures
BlueYard Capital
Possible Ventures
Taavet Sten
Acequia Capital
Henkel dx Ventures
Bayern Kapital
Alante Capital

   
Record changed: 2024-05-08

Advertisement

Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Insempra GmbH


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture Berlin Partner BIO 2024 International Convention San Diego 650x300px




» top